Flash e-reader

 Go to e-reader chapter








PDF FormatRequires Adobe Acrobat Reader

Table 8.6i

Immunosuppression Use for Antirejection Treatment from Transplant

to One Year Following Transplantation, 1999 to 2008

Recipients with Kidney-Pancreas Transplants

  Year of Transplant
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
Transplants 941 915 891 906 871 881 903 924 864 837
Tx with Antirejection Treatments 260 232 194 191 153 127 118 108 94 94
Antibodies Any in Category 42.3% 41.4% 32.0% 50.8% 58.2% 63.0% 50.8% 50.0% 51.1% 63.8%
Atgam/NRATG/NRATS 6.5% 3.9% 0.5% 2.6% 2.0% 3.1% 2.5% 2.8% 0.0% 1.1%
OKT3 24.6% 22.8% 12.4% 10.5% 9.8% 11.8% 11.0% 6.5% 9.6% 4.3%
Thymoglobulin 16.2% 15.1% 20.6% 34.0% 39.9% 44.1% 39.0% 35.2% 37.2% 50.0%
Zenapax 1.5% 1.7% 1.0% 4.7% 11.8% 7.1% 7.6% 9.3% 9.6% 10.6%
Simulect 0.4% 2.2% 0.5% 1.0% 1.3% 1.6% 0.0% 0.9% 0.0% 1.1%
Campath 0.0% 0.0% 0.0% 0.5% 3.9% 2.4% 0.0% 0.0% 2.1% 1.1%
Corticosteroids Any in Category 80.8% 82.8% 87.1% 76.4% 68.6% 68.5% 71.2% 68.5% 68.1% 52.1%
Steroids 80.8% 82.8% 87.1% 76.4% 68.6% 68.5% 71.2% 68.5% 68.1% 52.1%
Antimetabolites Any in Category 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.9% 0.0% 0.0%
Methotrexate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.9% 0.0% 0.0%


Source: OPTN/SRTR Data as of October 1, 2010.

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may

be prescribed more than one drug within the same category.